OSGear Introduces Updated Information Resources for Oral Steroids and Performance Research Products

New York, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) — Osgear has introduced updated information resources focused on oral steroids, performance research products, and related industry knowledge. The announcement highlights expanded educational material designed to provide structured information regarding product categories, research considerations, regulatory awareness, and responsible evaluation practices within the performance research sector.

TJGC Group Limited in Negotiations for AI and Robotics Technology License

HONG KONG, Aug. 10, 2026 (GLOBE NEWSWIRE) — TJGC Group Limited (Nasdaq: TJGC) (the “Company”) today announced it is negotiating a potential intellectual property license agreement with a robotics technology provider. The parties hope to enter into a definitive agreement granting the Company non-exclusive, worldwide rights to commercialize certain artificial intelligence and robotics technologies in intelligent automation products.

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately 76 months from the date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company’s common stock unless otherwise modified by the Board of Directors. After January 31, 2027, the quantity of these locked-up shares that can be sold daily and over various periods of time will be restricted under a leak-out plan unless otherwise modified by the Board of Directors.

New Peer-Reviewed Research Reinforces What the Data Has Shown for Years: Vaping Has Saved Canadian Lives

Ottawa, ON, Aug. 10, 2026 (GLOBE NEWSWIRE) — In response to a recent wave of alarming media coverage about vaping, the Canadian Vaping Association (CVA) is urging journalists, policymakers, and the public to look past the headlines and toward the growing body of peer-reviewed research on nicotine vaping products (NVPs) as a smoking-cessation and harm-reduction tool. 

From a Simple Idea to Thousands of Smiles: Teddy Bears On Call Celebrates 10 Years of Comforting Children in Crisis Through Its 3rd Annual Charity Golf Tournament

STATEN ISLAND, N.Y, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) — Teddy Bears On Call, Inc. (TBOC), a volunteer 501(c)(3) nonprofit organization dedicated to comforting children receiving emergency medical treatment, will host its Third Annual Charity Golf Tournament on Monday, Aug. 17, 2026, at Richmond County Country Club in Staten Island, New York. The “Golf for a Purpose” event will bring together golfers, business professionals, healthcare advocates, community leaders, sponsors and donors for a day of competition, networking, hospitality and philanthropy – all in support of TBOC’s mission to help children feel safer and less alone during some of the most frightening moments of their lives.

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational neuroscience R&D company, today announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure’s worldwide development and commercial rights to Privosegtor. This acquisition will result in the termination of Oculis’ existing license agreement with Accure, including associated milestone payments and royalties for each successful indication. This strategic transaction would enable Oculis to better harness Privosegtor’s potential value going forward, without the encumbrance of the legacy license agreement with Accure, while retaining greater economic upside for the asset’s future success as the Company continues to drive Privosegtor’s development and pursue potential expansion opportunities.

Global Power Solutions signs non-binding LOI with SolarZone Energy for potential deployment of modular power systems

Vancouver, BC, Canada, Aug. 10, 2026 (GLOBE NEWSWIRE) — Global Power Solutions Corp. (TSX Venture Exchange: PWER; Frankfurt Stock Exchanges: NJA) (“Global Power” or the “Company”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Solar Zone LLC, operating as SolarZone Energy (“SolarZone”), to evaluate the potential deployment of Global Power’s proposed 5 megawatt (“MW”) modular decentralized power systems across multiple sites in the United States.

Global Power Solutions signs non-binding LOI with SolarZone Energy for potential deployment of modular power systems

Vancouver, BC, Canada, Aug. 10, 2026 (GLOBE NEWSWIRE) — Global Power Solutions Corp. (TSX Venture Exchange: PWER; Frankfurt Stock Exchanges: NJA) (“Global Power” or the “Company”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Solar Zone LLC, operating as SolarZone Energy (“SolarZone”), to evaluate the potential deployment of Global Power’s proposed 5 megawatt (“MW”) modular decentralized power systems across multiple sites in the United States.